Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duloxetine versus placebo in children and adolescents with generalized anxiety disorder
2017-001599-46Phase 3
- Sponsor
- Eli Lilly and Company
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in generalized anxiety disorder (GAD) comparing Duloxetine with Placebo (2 arms). Primary endpoint: Change from baseline to 10-week endpoint in Pediatric Anxiety Rating Scale severity score for generalized anxiety symptoms.
02
Drugs
duloxetine
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on 2017-001599-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001599-46.